Implantable cardioverter-defibrillators in tetralogy of Fallot

Paul Khairy1, Louise Harris, Michael J Landzberg

  • 1Adult Congenital Heart Center, Montreal Heart Institute, 5000 Bélanger St, Montreal, Quebec, Canada H1T 1C8. paul.khairy@umontreal.ca

Circulation
|January 4, 2008
PubMed

Insights

Implantable cardioverter-defibrillators (ICDs) in Tetralogy of Fallot patients provide effective shock therapy but carry risks. High rates of appropriate shocks and lead complications necessitate careful consideration for these congenital heart disease patients.

Area of Science:

  • Cardiology
  • Congenital Heart Disease
  • Electrophysiology

Background:

  • Tetralogy of Fallot is the most common congenital heart disease in patients receiving implantable cardioverter-defibrillators (ICDs).
  • Limited data exists on the efficacy and safety of ICDs in this specific high-risk population.

Purpose of the Study:

  • To evaluate the effectiveness of ICDs in patients with Tetralogy of Fallot.
  • To identify risk factors for appropriate ICD discharges.
  • To characterize ICD-related complications and mortality rates.

Main Methods:

  • A multicenter cohort study involving 121 high-risk patients with Tetralogy of Fallot.
  • Patients received ICDs for primary or secondary prevention of sudden cardiac death.
  • Follow-up duration was a median of 3.7 years, assessing ICD discharges and complications.

Main Results:

  • 30.6% of patients received appropriate ICD discharges, with higher rates in secondary prevention.
  • Independent predictors for appropriate shocks in primary prevention included elevated left ventricular end-diastolic pressure and nonsustained ventricular tachycardia.
  • Inappropriate shocks occurred annually in 5.8% of patients, and 29.8% experienced complications, primarily late lead-related issues.

Conclusions:

  • Patients with Tetralogy of Fallot receiving ICDs experience substantial rates of appropriate shocks for ventricular arrhythmias.
  • High incidence of inappropriate shocks and late lead-related complications are significant concerns.
  • Annual mortality was 2.2%, with no significant difference between primary and secondary prevention groups.
Abstract

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...